Evidence map›Paper›PMID 40241581›Full record

ArticleCancer research and treatment2026

Cost-Effectiveness Analysis of Daratumumab Monotherapy and Subsequent Therapies in Heavily Treated Relapsed/Refractory Multiple Myeloma: A Feasible Methodology using a Korean Nationwide Population Cohort.

Sung-Soo Park, Suein Choi, Seungpil Jung, Seunghoon Han, Chaehyeon Lee, Jinseon Han, Soyoung Kim, Kihyun Kim, Chang-Ki Min

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sung-Soo ParkDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Suein ChoiDivision of Data Science, Catholic Research Network for Multiple Myeloma, Seoul, Korea.
Seungpil JungDivision of Data Science, Catholic Research Network for Multiple Myeloma, Seoul, Korea.
Seunghoon HanDepartment of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chaehyeon LeeDivision of Data Science, Catholic Research Network for Multiple Myeloma, Seoul, Korea.
Jinseon HanDepartment of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Soyoung KimInnovation Center for Industrial Mathematics, National Institute for Mathematical Sciences, Seongnam, Korea.
Kihyun KimDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Chang-Ki MinDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Funding

Ministry of Food and Drug Safety RS-2023-00216446Ministry of Science and ICTNational Institute for Mathematical Sciences NIMS-B24810000
6 · The paper itself

Abstract

purposeHigh-cost novel therapies for multiple myeloma (MM) require evaluation of efficacy and cost-effectiveness. MATERIALS AND

methodsThis study developed a methodology to assess cost-effectiveness using nationwide data from 11,450 newly diagnosed MM patients. A novel algorithm was applied to identify lines of therapy (LoT).

resultsThe number of newly diagnosed MM patients increased significantly, from 873 in 2010 to 1,464 in 2019 (p < 0.001). Advancing LoT was associated with shorter time to next treatment (TTNT) and overall survival (OS) (p < 0.001), while all-cause medical costs increased with each LoT (p < 0.001). Bortezomib-melphalan-prednisolone was the most common frontline regimen for transplant-ineligible patients (29.2%), while bortezomib-thalidomide-dexamethasone was most used for transplant-eligible patients (11.3%). Daratumumab monotherapy demonstrated superior second TTNT (7.8 vs. 5.2 months) and OS (8.5 vs. 5.3 months) compared to standard care in heavily treated MM patients, with statistical significance maintained after cost adjustment. For subsequent therapies following daratumumab, a methodology was developed to estimate required medical costs using the incremental cost-effectiveness ratio (ICER): Expected cost ($)=ICER×(Expected life expectancy-0.567)+35,601.

conclusionThis study provides a novel cost-effectiveness framework linking treatment efficacy and real-world costs, supporting predictions of societal costs for future MM therapies.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCost-Benefit AnalysisMultiple MyelomaNeoplasm Recurrence, LocalAdultAgedAged, 80 and overCost-Effectiveness AnalysisFemaleHumansMaleMiddle AgedRepublic of KoreaAntibodies, MonoclonaldaratumumabAdoptive immunotherapyBispecific antibodiesCost-effectivenessDaratumumabMultiple myeloma

Identifiers

PMID40241581
PMCPMC12800944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.